Survodutide, an experimental once-weekly injected medication imitating an appetite-curbing gut hormone and the liver-acting hormone glucagon, targets weight and liver fat; unapproved, it is available only in research studies. Manufacturer-funded trials show sustained weight loss, large liver fat reductions, better blood sugar control in type 2 diabetes and lower blood pressure; digestive side effects are very common. Benefits in lean, healthy people, long-term heart safety and healthy-aging role remain unknown. (Full Review)

Protocol

Phase 3 obesity regimen

3.6 or 6.0 mg once weekly

Subcutaneous injection escalated to a maintenance dose; used for 76 weeks in SYNCHRONIZE-1 and -2

Escalation

20–24 weeks

20 weeks in phase 2; 24 weeks to 6.0 mg in SYNCHRONIZE-MASLD; phase 3 allowed delays or one-level reductions for 2–4 weeks

Lifestyle context

~500 kcal/day deficit

Paired with physical-activity counseling in SYNCHRONIZE-1 and -2

Time to effect

Weight loss

46–76 weeks

Loss continues through 46–76 weeks

Liver fat

48 weeks

Liver-fat reduction measured at 48 weeks

Appetite

First weeks

Appetite drops within the first weeks

Benefits

Medium: Weight and Visceral Fat Loss; Better Blood Sugar Control in Type 2 Diabetes; Liver Fat Clearance in MASLD; Lower Blood Pressure; MASH Improvement and Fibrosis Regression

Speculative: Fewer Cardiovascular Events; Lower Triglycerides; Lower Systemic Inflammation; Kidney Protection; Improved Insulin Sensitivity and Beta-Cell Function; Higher Energy Expenditure

Contraindications

Personal or family history of medullary thyroid carcinoma or MEN2

History of acute or chronic pancreatitis, or lipase or amylase above 2× the upper limit of normal

Heart failure (NYHA functional class IV, symptoms even at rest)

Clinically significant gastric emptying disorders (severe gastroparesis, gastric outlet obstruction)

Type 1 diabetes

Pregnancy, breastfeeding or planned pregnancy

Adults with BMI below 27 kg/m² (below 24 kg/m² in the Chinese trial)

Key Interactions

Insulin and sulfonylureas (glimepiride, gliclazide, glyburide): caution (theoretical for survodutide)

Other GLP-1-based drugs (semaglutide, tirzepatide, liraglutide) and DPP-4 inhibitors (sitagliptin, linagliptin): avoid (theoretical)

Oral drugs with narrow dosing margins (warfarin, levothyroxine) and oral contraceptives: monitor (theoretical)

Antihypertensives (lisinopril, losartan, amlodipine, metoprolol, diuretics): monitor

SGLT2 inhibitors (empagliflozin, dapagliflozin) and diuretics (furosemide, hydrochlorothiazide): caution (theoretical)

Over-the-counter NSAIDs (ibuprofen, naproxen): caution (theoretical)

Over-the-counter acetaminophen and other oral tablets: monitor

Glucose-lowering supplements (berberine, chromium, cinnamon, alpha-lipoic acid): monitor (theoretical)

Blood-pressure-lowering supplements (garlic extract, hibiscus, magnesium, potassium): monitor (theoretical)

Stimulant weight-loss supplements (high-dose caffeine, synephrine, yohimbine): avoid (theoretical)

Fiber supplements (psyllium, glucomannan): monitor (theoretical)

Alcohol: caution (theoretical)

Prolonged fasting or very-low-calorie diets: caution (theoretical)

Procedures under sedation or general anesthesia: caution (theoretical)

Risk & Side Effects

Medium: Gastrointestinal Adverse Events and Treatment Discontinuation; Increased Resting Heart Rate

Low: Excessive Appetite Suppression; Loss of Lean Mass; Gallbladder Disease; Acute Pancreatitis; Low Blood Pressure; Dehydration and Acute Kidney Injury; Hypoglycemia With Diabetes Medications; Mood Changes; Worsening Diabetic Retinopathy; Aspiration Risk During Anesthesia; Weight Regain After Stopping

Speculative: Medullary Thyroid Cancer; Amino Acid Depletion

Monitoring

Marker	Target	Why
Body weight and waist circumference	No established target; track % change from own baseline	Expected to change
HbA1c	4.0–5.6%	Expected to change
Fasting glucose	70–99 mg/dL	Safety check (hypoglycemia) and expected to change
Lipase and amylase	Within laboratory reference range	Safety check (pancreatitis)
ALT	Below 43 U/L in women, below 48 U/L in men	Expected to change and safety check
Liver fat (MRI-PDFF)	Below 5%	Expected to change
Resting heart rate	60–100 beats per minute	Safety check (heart-rate rise)
Blood pressure	No established target; track change from own baseline	Expected to change and safety check (hypotension)
Serum creatinine	0.6–1.2 mg/dL	Safety check (dehydration-related kidney injury)
Triglycerides	Below 150 mg/dL	Expected to change
Lean mass by DXA	No established target; track change from own baseline	Expected to change (lean-mass loss)

Cadence: Baseline before the first injection; weight, blood pressure and heart rate every 2–4 weeks during dose escalation, then every 6–12 weeks during maintenance; blood tests at 3 months, then every 6 months; liver fat imaging and body composition at 12 months

Qualitative Assessment

Nausea, vomiting and bowel habits, especially in the days after each dose increase
Appetite and "food noise" (intrusive thoughts about food)
Energy levels and exercise capacity
Strength in regular lifts or grip tests
Mood and motivation
Sleep quality and snoring
Palpitations or dizziness on standing

Survodutide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment